Nycomed Amersham Imaging
This article was originally published in The Gray Sheet
Executive Summary
Firm commences Phase I clinical trial of lung imaging agent NC100182 to document safety following investigational new drug approval. Based on "spin signal" technology, the firm "is hopeful that potential applications will include use in patients with asthma, cystic fibrosis, chronic obstructive lung disease such as emphysema and patients undergoing transplantation and lung volume reduction surgery." The technology was derived in part through the acquisition of Magnetic Imaging Technologies last year. The Phase I trial is expected to close in the fall and a Phase II trial examining the agent could begin in early 2001
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.